New Evidence Confirms Safety and Efficacy of Lecanemab for Early-Stage Alzheimer’s
Recent studies reaffirm the safety and effectiveness of lecanemab in slowing Alzheimer’s progression, with rare manageable side effects observed in early-stage patients.
Lecanemab: A New Hope in Alzheimer’s Treatment
The FDA approved the drug lecanemab, marketed as Leqembi, in 2023 for treating Alzheimer’s disease. Recent real-world studies affirm its safety, showing that serious side effects like amyloid-related imaging abnormalities (ARIA) are rare and manageable, especially when used early.
Lecanemab is a type of antibody designed to target amyloid proteins in the brain, which form plaques associated with Alzheimer’s. Clinical trials have demonstrated that patients receiving lecanemab experienced a 25-30% slower decline in cognitive functions over 18 months compared to untreated groups. Imaging effects also showed reductions or clearance of amyloid plaques.
A new study published in JAMA Neurology involving 234 patients at Washington University observed that only 1.8% of those with very mild Alzheimer’s symptoms showed ARIA symptoms, compared to 27% in those with more advanced stages. Most ARIA cases were mild and resolved within months, with no fatalities.
Experts highlight that early diagnosis is crucial as early-stage patients benefit the most. Continued research aims to better identify individuals at higher risk of ARIA, to optimize treatment safety.
While lecanemab offers hope, physicians emphasize careful patient selection and monitoring to balance benefits against risks such as side effects and ARIA. Ongoing studies and real-world data will help refine these treatments and expand options for managing Alzheimer’s disease.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Global Increase in Gastrointestinal Cancers Spotlighted by Recent Literature Review
Recent studies reveal a global surge in gastrointestinal cancers among young adults, highlighting the urgent need for improved screening and prevention strategies. Early-onset GI cancers, including colorectal, gastric, and pancreatic, are increasing rapidly, especially in vulnerable populations.
'Good' Gut Bacteria Promote Placenta Health and Support Healthy Pregnancy
Discover how beneficial gut bacteria like Bifidobacterium breve influence placental hormone production and support healthy pregnancy outcomes, opening new possibilities for prenatal health interventions.
Emerging Threat: Blood-Sucking Insects in the US Spread Deadly Parasite
A parasitic disease transmitted by kissing bugs is spreading across the US, with potential to cause serious health complications. Learn about the risks and prevention measures for Chagas disease.
Establishing a National Standard for Safe and Scalable AI in Healthcare
Duke University researchers have developed pioneering frameworks to evaluate the safety and performance of AI models in healthcare, advancing responsible AI adoption with scalable assessment tools for clinical settings.